Continued ICP Orders From Japanese Customers NEW HAVEN, Conn., March 05, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that it continues to receive both new and repeat business from...

Precipio Expands ICE-COLD PCR™ Lung Cancer Mutation Detection Offering New kit examines most relevant EGFR exons that impact therapeutic decisions for lung cancer patients NEW HAVEN, Conn., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Precipio, Inc. (NASDAQ: PRPO), announced...

Precipio Launches Unique Lung Cancer Monitoring Test for Therapy Resistance NEW HAVEN, Conn., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Precipio, Inc. (NASDAQ:PRPO) announced today its launch of the first lung cancer treatment resistance panel specifically for the critical...

Exosome Diagnostics Publishes a Study Demonstrating Superior Performance of ExoLution™ Plus Liquid Biopsy Platform in Lung Cancer Waltham, MA, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc., recently published a study in the Journal Annals of Oncology, of EGFR Liquid Biopsy detection in patients with Non-Small...